
Guggenheim lowered the firm’s price target on Absci (ABSI) to $14 from $15 and keeps a Buy rating on the shares after updating the firm’s model following Absci’s Q3 results
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ABSI | AbSci | 8.18 | 5.09 | 165.03% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.18 | +165.03% |

Guggenheim lowered the firm’s price target on Absci (ABSI) to $14 from $15 and keeps a Buy rating on the shares after updating the firm’s model following Absci’s Q3 results

Absci Corp. (($ABSI)) has held its Q3 earnings call. Read on for the main highlights of the call. Absci Earnings Call: Hair-Loss Trial Nears Key Readout The call carried a

08:47 EST Absci (ABSI) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended

Reports Q3 revenue $304,000, consensus $581,700. “As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for

An announcement from AbSci ( ($ABSI) ) is now available. On November 12, 2026, Absci reported third-quarter operating results and business updates, including continued dosing in the HEADLINE trial of

Absci (ABSI) announced the appointment of Gerry Muhle as chief commercial officer. Muhle will lead Absci’s commercial strategy, bringing experience in commercializing prescription medicines and building consumer brands to advance

Absci Corp. (ABSI) is scheduled to report 3rd quarter earnings on 11/12/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Absci Corp. to post earnings of -$0.19

Jefferies analyst Andrew Tsai initiated coverage of Absci (ABSI) with a Buy rating and $14 price target ABS-201 is approaching two near-term value-inflection points for pattern hair loss, the analyst

AbSci, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $16.00

KeyBanc raised the firm’s price target on Absci (ABSI) to $20 from $16 and keeps an Overweight rating on the shares. Into the setup for Q3 earnings, the firm saw
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Assigned | Nov 18, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Initiated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 16, 2026 | ||||
| buy | Reiterated | Oct 12, 2026 | ||||
| buy | Reiterated | Oct 6, 2026 | ||||
| buy | Reiterated | Sep 30, 2026 | ||||
| buy | Reiterated | Sep 24, 2026 | ||||
| buy | Reiterated | Sep 23, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 23, 2027TBA | $1.31B | $-0.20 | $770.00K | 0.39 | -9.50 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.